RVMD Director Elizabeth Anderson Exercises Options & Sells Shares

What Happened

• Elizabeth M. Anderson, a director of Revolution Medicines (RVMD), exercised options to acquire 5,070 shares at $1.12 per share (cost $5,678) and, on the same day (Sept 22, 2026), sold 10,143 shares in multiple open‑market transactions for aggregate proceeds of $1,958,015. The sales were executed under a pre-existing 10b5‑1 trading plan.

Key Details

• Transaction date: September 22, 2026; Form filed Sept 24, 2026 (timely).
• Option exercise: 5,070 shares acquired at $1.12 each (total $5,678) — reporting code M.
• Sales (open market): five blocks — 910 @ $191.85, 4,985 @ $192.54, 2,648 @ $193.44, 1,500 @ $194.59, 100 @ $195.15; total sold = 10,143 shares; gross proceeds ≈ $1,958,015.
• Reported trade price ranges across the blocks: approximately $191.65 to $194.96 (see footnotes F2–F5 for per‑trade ranges and weighted averages).
• Footnotes: F1 = transactions pursuant to a 10b5‑1 plan adopted June 23, 2026; F6 = includes 1,191 restricted stock units; F7/F8 indicate certain shares held in trusts; F9 = fully vested.
• Shares owned after the transactions are not explicitly stated in the summary data provided here — see the full Form 4 for current holdings details.

Context

• Code M indicates option exercise/derivative conversion. Because the exercise and multiple sales occurred the same day and the sales were made under a 10b5‑1 plan, this sequence is consistent with an exercise followed by planned dispositions (often used to cover exercise cost/taxes or reallocate holdings). This filing is factual disclosure of the transactions and does not indicate motive.